top of page

CVMP Meeting of 17-19 January 2017

The CVMP adopted a positive opinion for a grouped type II variation for RESPIPORC FLU3 regarding quality changes and for multiple type IB variations. The CVMP adopted positive opinions for the renewal of the marketing authorisations for Nobivac L4 and Porcilis ColiClos. They also reviewed the PSURs for Bravecto, Broadline and Osurnia and recommended amendments to their product literature and requested for Bravecto a targeted PSUR on all serious AE reports.



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page